
Biotech Gap Risk: Why a Planned 5% Exit Can Become a Larger Loss
A viewer asked how technical traders handle a biotech stock that moves sharply on clinical news. Steve Strazza’s answer began with accepting the limits of a stop and spreading exposure across a basket.







